Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?
Curr Vasc Pharmacol
.
2016;14(1):76-9.
doi: 10.2174/157016111401151126161741.
Authors
Niki Katsiki
,
Georgios A Christou
,
Dimitrios N Kiortsis
1
Affiliation
1
Laboratory of Physiology, Medical School, University of Ioannina, 45110 Ioannina, Greece. dkiorts@cc.uoi.gr.
PMID:
26642873
DOI:
10.2174/157016111401151126161741
No abstract available
Publication types
Editorial
Comment
MeSH terms
Female
Glucagon-Like Peptide 1 / analogs & derivatives*
Humans
Hypoglycemic Agents / administration & dosage*
Male
Obesity / drug therapy*
Substances
Hypoglycemic Agents
Glucagon-Like Peptide 1